Analysis of physiological markers of bone remodeling, muscle strength, functional autonomy, self-esteem and self-image in elderly undergoing adapted Taekwondo

Start Date06 Feb 2022

Sponsor / Collaborator

Universidade Estácio de Sá

[+1]

RBR-3xr6dv

/ RecruitingNot ApplicableIIT

Comparison between 0,4% Oxibuprocaine corneal anesthesia applied by Eyedrops or Spray

Start Date27 Jun 2019

Sponsor / Collaborator

Universidade Estácio de Sá

[+1]

RBR-4gjhfk

/ Not yet recruitingPhase 4IIT

Anesthetic effect of Proximetacaine hydrochloride 0,5%: comparison between eyedrop instillation in open eyes and vaporization in closed eyes

Start Date01 Oct 2018

Sponsor / Collaborator

Universidade Estácio de Sá

[+1]

100 Clinical Results associated with Universidade Estácio de Sá

0 Patents (Medical) associated with Universidade Estácio de Sá

687

Literatures (Medical) associated with Universidade Estácio de Sá

01 Feb 2025·Multiple Sclerosis and Related Disorders

Retraction Notice to “New relapse of multiple sclerosis and neuromyelitis optica as a potential adverse event of AstraZeneca AZD1222 vaccination for COVID-19” [Multiple Sclerosis and Related Disorders 57 (2022) 103321]

Article

Author: Peron, Jean Pierre S ; Tauil, Carlos Bernardo ; de Oliveira, Bianca Etelvina S ; Gonçalves, Marcus Vinicius M ; Rocha, Cristiane Franklin ; Fragoso, Yara D ; Mendes, Junior Euldes ; Gomes, Sidney ; Araujo, Raquel Vassao ; Cruz Dos Santos, Gutemberg A

This article has been retracted: please see Elsevier Policy on Article Withdrawal (https://www-elsevier-com.libproxy1.nus.edu.sg/about/policies/article-withdrawal). This article has been retracted at the request of the authors. The authors would like to express their deepest apologies for the error contained in their article and for any concerns or misunderstandings it may have caused. Specifically, the article mistakenly mentioned the presence of the MF59 adjuvant in the AZD1222 vaccine formulation, which is incorrect.

12 Nov 2024·Circulation

Abstract 4146436: Echocardiography Analysis of Anabolic-Androgenic Steroids Effects on Cardiac Structure and Function in Athletes: A Systematic Review and Meta-Analysis

Author: Cavalcante, Douglas ; De Oliveira Fischer Bacca, Caroline ; Melo, Altair ; Fante, Gustavo Eduardo ; Romariz, Livia

Introduction: Anabolic-androgenic steroids (AAS) have been used for performance enhancement by athletes, exposing them to potential cardiovascular effects and structural changes. Some athletes also present cardiac structural or functional changes secondary to resistance training. Therefore, the true effect of AAS in echocardiographic parameters among athletes remains unclear. Research Question: What are the changes in echocardiographic parameters in athletes who use AAS compared with those who do not use AAS. Objective: We aimed to perform a systematic review and meta-analysis comparing use with no use of AAS in athletes for echocardiography parameters. Methods: PubMed, Embase, and Cochrane were systematically searched for studies that assessed echocardiographic changes in athletes who used AAS compared to non-users. We computed mean differences (MD) for all continuous outcomes, with 95% confidence intervals (CI) pooled under a random-effects model. Heterogeneity was assessed with I 2 statistics. Statistical analysis was performed using Review Manager (Cochrane Collaboration). Results: We included 13 studies with 742 male athletes (401 AAS vs 341 control; mean age 33.4 and 32.4 years respectively). AAS was associated with a decrease left ventricular (LV) ejection fraction (MD -3.17%; 95% CI -5.51, -0.83%; p=0.008; Figure 1A) and global longitudinal strain (MD 3.58%; 95% CI 2.95, 4.20%; p<0.001; Figure 1B) when compared to no use. Athletes who used AAS also had an increased septal wall thickness (MD 0.98 mm; 95% CI 0.06, 1.9 mm; p=0.04; Figure 2A.), posterior wall thickness (MD 1.16 mm; 95% CI 0.57, 1.75 mm; p<0.01; Figure 2B) and LV mass (MD 42.9g; 95% CI 23.2, 62.5g; p<0.0001; Figure 2C) when compared to non-user athletes. LV end-diastolic diameter (MD 1.26mm; 95% CI 0.00, 2.51mm; p=0.05; Figure 2D) showed a tendency to increase in AAS users, but with no significant difference. Conclusion: AAS use among athletes is associated with reduced LV function and increased LV hypertrophy and overload, compared with athletes who do not use AAS.

02 Oct 2024·Expert Review of Cardiovascular Therapy

Nattokinase as an adjuvant therapeutic strategy for non-communicable diseases: a review of fibrinolytic, antithrombotic, anti-inflammatory, and antioxidant effects

Review

Author: Mesquita, Claudio Tinoco ; Cardozo, Ludmila FMF ; Ribeiro, Marcia ; Alvarenga, Livia ; Carvalhosa, Priscila ; Stockler-Pinto, Milena Barcza ; Granito, Mariana ; Andrade, Thaysi ; Mafra, Denise

INTRODUCTIONNattokinase (NK) is the primary ingredient of natto, a traditional Asian food made from fermented soybean by Bacillus subtilis natto. Studies have shown that natto reduces the risk of cardiovascular disease (CVD) mortality due to its fibrinolytic and antithrombotic properties. A new field of studies also demonstrates that NK can mitigate molecular pathways related to inflammation and oxidative stress and can be considered an adjuvant strategy for use in many non-communicable diseases (NCDs). This paper is a narrative review of the literature. A search was conducted in PubMed and ScienceDirect up to July 2024.AREAS COVEREDThis review discusses the possible effects of NK on mitigating the common complications of NCDs, such as inflammation and oxidative stress. In addition, it provides an update on the most addressed areas related to NK's fibrinolytic and antithrombotic activities.EXPERT OPINIONDue to the fibrinolytic and antithrombotic activity of nattokinase, and more recently added to the anti-inflammatory and antioxidant effects, this enzyme can be used as a new adjuvant therapeutic strategy to mitigate inflammation and oxidative stress in NCDs, including CVD.

100 Deals associated with Universidade Estácio de Sá

100 Translational Medicine associated with Universidade Estácio de Sá

Corporation Tree

Boost your research with our corporation tree data.

view full example data

Pipeline

Pipeline Snapshot as of 24 Jan 2025

No data posted

Deal

Boost your decision using our deal data.

view full example data

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Profit

Explore the financial positions of over 360K organizations with Synapse.

view full example data

Grant & Funding(NIH)

Access more than 2 million grant and funding information to elevate your research journey.

view full example data

Investment

Gain insights on the latest company investments from start-ups to established corporations.

view full example data

Financing

Unearth financing trends to validate and advance investment opportunities.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis